A recently published report presented at the 2019 AIBD Annual Meeting in Orlando, FL, discussed the case of a patient who developed ulcerative colitis (UC) following treatment with Secukinumab for her psoriatic arthritis and highlighted a novel approach for the management of both of her conditions simultaneously.
Using ultrasound, researchers evaluated the anatomic basis for arthralgia in patients with psoriasis; they also explored the rate of psoriatic arthritis development in patients with psoriasis with and without arthralgia.
The five-year incidence rate of joint surgery in psoriatic arthritis (PsA) patients is twice as high as in the general population, and this rate has remained steady over time.
Investigators analyzed the prescribing practices for patients with psoriatic arthritis at an urban rheumatology office, with an emphasis on biologic prescribing.
AbbVie announced positive topline data from the phase 3 SELECT-PsA 2 trial of upadacitinib (Rinvoq) in patients with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response to ≥1 biologic disease modifying anti-rheumatic drugs (bDMARDs).
Researchers evaluated the effect of filgotinib vs placebo on the health-related quality of life in patients with psoriatic arthritis from the EQUATOR study.
Researchers compared the efficacy and safety of ixekizumab with adalimumab in patients with both active psoriatic arthritis and joint and skin disease and with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Researchers investigated the protein expression of interleukin (IL)-41 in the synovial tissue of patients with psoriatic arthritis, rheumatoid arthritis, and osteoarthritis and evaluated the production of IL-41 from the enthesis.
